Institut für Experimentelle Onkologie und Therapieforschung des Klinikums rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675 Munich, Germany.
Clin Exp Metastasis. 2011 Dec;28(8):793-802. doi: 10.1007/s10585-011-9410-z. Epub 2011 Jul 26.
In many different tumor entities, increased expression of tissue inhibitor of metalloproteinases-1 (Timp-1) is associated with poor prognosis. We previously reported in mouse models that elevated systemic levels of Timp-1 induce a gene expression signature in the liver microenvironment increasing the susceptibility of this organ to tumor cells. This host effect was dependent on increased activity of the hepatocyte growth factor (Hgf)/hepatocyte growth factor receptor (Met) signaling pathway. In a recent study we showed that Met signaling is regulated by Timp-1 as it inhibits the Met sheddase A disintegrin and metalloproteinase-10 (Adam-10). The aim of the present study was to elucidate whether the metastatic potential of tumor cells benefits from autocrine Timp-1 as well and involves Adam-10 and Met signaling. In a syngeneic murine model of experimental liver metastasis Timp-1 expression and Met signaling were localized within metastatic colonies and expressed by tumor cells. Knock down of tumor cell Timp-1 suppressed Met signaling in metastases and inhibited metastasis formation and tumor cell-scattering in the liver. In vitro, knock down of tumor cell Timp-1 prevented Hgf-induced Met phosphorylation. Consequently, knock down of Met sheddase Adam-10 triggered auto-phosphorylation and responsiveness to Hgf. Accordingly, Adam-10 knock down increased Met phosphorylation in metastatic foci and induced tumor cell scattering into the surrounding liver parenchyma. In conclusion, these findings show that tumor cell-derived Timp-1 acts as a positive regulator of the metastatic potential and support the concept that proteases and their natural inhibitors, as members of the protease web, are major players of signaling during normal homeostasis and disease.
在许多不同的肿瘤实体中,组织金属蛋白酶抑制剂-1(Timp-1)的表达增加与预后不良有关。我们之前在小鼠模型中报告说,系统中 Timp-1 水平的升高会诱导肝脏微环境中的基因表达特征,增加该器官对肿瘤细胞的易感性。这种宿主效应依赖于肝细胞生长因子(HGF)/肝细胞生长因子受体(Met)信号通路活性的增加。在最近的一项研究中,我们表明 Met 信号受 Timp-1 调节,因为它抑制了 Met 脱落酶 A 型整合素金属蛋白酶-10(Adam-10)。本研究的目的是阐明肿瘤细胞的转移潜能是否也受益于自分泌 Timp-1,并涉及 Adam-10 和 Met 信号。在实验性肝转移的同基因小鼠模型中,Timp-1 表达和 Met 信号定位于转移性集落内,并由肿瘤细胞表达。肿瘤细胞 Timp-1 的敲低抑制了转移部位的 Met 信号,并抑制了转移的形成和肿瘤细胞在肝脏中的分散。在体外,肿瘤细胞 Timp-1 的敲低阻止了 Hgf 诱导的 Met 磷酸化。因此,Met 脱落酶 Adam-10 的敲低触发了自身磷酸化和对 Hgf 的反应性。相应地,Adam-10 的敲低增加了转移灶中的 Met 磷酸化,并诱导肿瘤细胞散布到周围的肝实质中。总之,这些发现表明肿瘤细胞来源的 Timp-1 是转移潜能的正调节剂,并支持这样的概念,即蛋白酶及其天然抑制剂作为蛋白酶网络的成员,在正常的体内平衡和疾病过程中是信号转导的主要参与者。